1. Market Research
  2. > Healthcare
  3. > Diagnostics Market Trends
  4. > 2015 Global Survey on Liquid Biopsy Adoption Trends

2015 Global Survey on Liquid Biopsy Adoption Trends

  • November 2015
  • -
  • Frost & Sullivan
  • -
  • 86 pages

Learn the Promising Technologies and Bottlenecks for CTCs and ctDNA—A Voice of Customer Study

The primary goal of this research is to analyze the current and future adoption patterns on the usage of liquid biopsy. Key information the survey seeks to collect include the following:
- Current and future use of liquid biopsy by organization type
- Timeframe of liquid biopsy adoption amidst future users
- Predominantly used cell types—CTCs, ctDNA, cfDNA and Evs—by organization type
- Sample inflow to conduct liquid biopsy tests
- Preference for sample types: blood, saliva, stool, serum, and so on.
- Correlation analysis of sample type and biomarker type
- Promising applications for liquid biopsy—current and future
- Predominant approaches to liquid biopsy: hotspot panels, single marker tests, and so on
- Technologies used to detect CtDNA—current vs. future users
- Technologies used to detect CTCs
- Vendor popularity for specific biomarkers and reimbursement scenario
- Bottlenecks to mainstream implementation of liquid biopsy

Research Objectives
The primary goal of this research is to analyze the current and future adoption patterns on the usage of liquid biopsy. Key information the survey seeks to collect include the following:
- Current and future use of liquid biopsy by organization type
- Timeframe of liquid biopsy adoption amidst future users
- Predominantly used cell types—CTCs, ctDNA, cfDNA and EVs—by organization type
- Sample inflow to conduct liquid biopsy tests
- Preference for sample types: blood, saliva, stool, serum, and so on.
- Correlation analysis of sample type and biomarker type
- Promising applications for liquid biopsy—current and future
- Predominant approaches to liquid biopsy: hotspot panels, single marker tests, and so on
- Technologies used to detect ctDNA—current vs. future users
- Technologies used to detect CTCs
- Vendor popularity for specific biomarkers and reimbursement scenario
- Bottleneck to mainstream implementation of liquid biopsy

Research Methodology

Methodology
Clinical and Research Laboratories were invited to participate in an online survey in July 2015. To qualify for survey participation, respondents must work within a private or public laboratory, academic research facility, hospital lab or a pharmaceutical or diagnostic company that employs liquid biopsy technologies. Respondents should be a constant user of liquid biopsy technologies, belong to the scientific community, and be in a position to authorize purchases and handle laboratory budgets.

Sample
The target group was screened to ensure only qualified respondents participated. In total, decision makers qualified for the survey, representing the following types of laboratories:

Pharmaceutical and diagnostic companies
Research institutes and universities
Hospital laboratories
Reference laboratories (includes CLIA-/CAP-certified laboratories)

Reporting Notes
- Respondents indicated a wide range of job titles, such as lab directors, scientists, lab managers, oncologists, clinicians, pathologists, and lab technicians.
- In total, about % of respondents work in the United States, and about % work in Europe. Nevertheless, this study is considered global because the survey was open to respondents from all countries.
- Due to rounding, percentages in charts and tables may not sum to .

Table Of Contents

2015 Global Survey on Liquid Biopsy Adoption Trends
Research Background, Objectives, Methodology, and Respondent Demographics
Research Objectives
Research Methodology
Respondent Demographics
Respondent Demographics—Current and Future Users

Executive Summary
Key Findings
Top 7 Brands for Liquid Biopsy

Overall Usage of Liquid Biopsy
Overall Use of Liquid Biopsy by Organization Type
Timeframe for Future Adoption
Timeframe for Adoption by Organization Type
Opinion on Use of Liquid Biopsy as an Adjunct to Tissue Biopsy
Liquid Biopsy as an Adjunct to Tissue Biopsy (continued)

Preferred Cell Types and Sample Types for Liquid Biopsy
Overall Biomarker Usage
Overall Biomarker Usage—Hospital Laboratories
Overall Biomarker Usage—Pharmaceutical and Diagnostic Companies
Overall Biomarker Usage—Reference Laboratories*
Overall Biomarker Usage—Research Institutes and Universities

Workload Assessment
Sample Volume Per Month
Sample Format—Overall
Sample Format—Current Users vs. Future Users
Sample Format by Organization Type

Predominantly Used Technologies
Technologies Used to Detect ctDNA—Overview
Technologies Used to Detect ctDNA—Current and Future User Trends
Technologies Used to Detect ctDNA by Organization Type
Technologies Used to Detect CTC—Overview
Technologies Used to Detect CTC—Current and Future User Trends
Technologies Used to Detect CTC by Organization Type

Liquid Biopsy—Promising Applications and Bottlenecks
Brand Familiarity for Tumor Profiling
Promising Applications of Liquid Biopsy (Overall)
Promising Applications by Organization Type
Promising Applications—Current and Future Users
Bottlenecks in Liquid Biopsy
Bottlenecks by Biomarker Type

Tumor Profiling Approaches, Technologies for Detection
Liquid Biopsy Usage to Profile Types
Tumor Profiling by Organization Type
Liquid Biopsy Approaches—Current vs. Future Users
Liquid Biopsy Approach by Organization Type
Correlation of Sample Type and Liquid Biopsy Approach
CTC-Specific Liquid Biopsy Approaches—Current vs. Future Users
ctDNA-Specific Liquid Biopsy Approaches—Current vs. Future Users
Germline or cfDNA-Specific Liquid Biopsy Approaches—Current vs. Future Users
EVs-Specific Liquid Biopsy Approaches—Current vs. Future Users

Brand Perception
Overall Brand Perception
Brand Perception Organization Type
Top 7 Current and Future Brand Perception
Brand Preference by Biomarker Type—CTCs
Brand Preference by Biomarker Type—CtDNA
Brand Preference by Biomarker Type—Germline and cfDNA
Brand Preference by Biomarker Type—Evs

Reimbursement Scenario
Reimbursement Trends (Overall)
Reimbursement Trend by Organization Type
Reimbursement by Technology—ctDNA
Reimbursement by Technology—CTC

Mutant Allele Limit (Verbatim Reponses)
Mutant Allele Detection Limit—Diagnosis and Monitoring

Reasons for Preferring Blood as a Sample Type(Verbatim Reponses)
Reasons for Choosing Blood Over Other Sample Types
Legal Disclaimer

Appendix
Additional Sources of Information

The Frost and Sullivan Story
Value Proposition—Future of Your Company and Career
North America and Europe Perspective
Industry Convergence
360º Research Perspective
Implementation Excellence
Our Blue Ocean Strategy

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Liquid Biopsy Market: Global Industry Analysis and Opportunity Assessment 2016-2026

Liquid Biopsy Market: Global Industry Analysis and Opportunity Assessment 2016-2026

  • $ 5000
  • Industry report
  • August 2016
  • by Future Market Insight Global & Consulting Pvt Ltd

Report Synopsis This report by Future Market Insights (FMI) examines the ‘Liquid Biopsy Market’ for the period 2016–2026. The primary objective of the report is to offer updates and information ...

Breast Biopsy Device Market Analysis By Test Type, By Product, By Guidance Type, By Region And Segment Forecasts To 2024

Breast Biopsy Device Market Analysis By Test Type, By Product, By Guidance Type, By Region And Segment Forecasts To 2024

  • $ 4950
  • Industry report
  • August 2016
  • by Grand View Research

The breast biopsy device market is expected to reach USD 911.2 million by 2024, according to a new report by Grand View Research, Inc. The Breast biopsy device market is projected to grow at a productive ...

Liquid Biopsy Market Size & Forecast By Application, By Sample Type, By Biomarker Type, By Technology and Trend Analysis from 2013 to 2030

Liquid Biopsy Market Size & Forecast By Application, By Sample Type, By Biomarker Type, By Technology and Trend Analysis from 2013 to 2030

  • $ 4950
  • Industry report
  • September 2016
  • by Grand View Research

Global liquid biopsies market is anticipated to reach 5,958.3 million by 2030, according to a new report by Grand View Research, Inc. As these less invasive biopsies are able to address a number of significant ...


Download Unlimited Documents from Trusted Public Sources

Biopsy Industry in the US

  • October 2016
    7 pages
  • Biopsy  

    Magnetic Resona...  

    Cancer  

  • United States  

View report >

Biopsy Industry in the US

  • August 2016
    2 pages
  • Biopsy  

  • United States  

    North America  

View report >

Biopsy Industry in the US

  • August 2016
    4 pages
  • Biopsy  

  • United States  

View report >

Related Market Segments :

Biopsy

ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.